BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33682326)

  • 21. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
    Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
    Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE).
    de Tersant M; Généré L; Freyçon C; Villebasse S; Abbas R; Barlier A; Bodet D; Corradini N; Defachelles AS; Entz-Werle N; Fouquet C; Galmiche L; Gandemer V; Lacour B; Mansuy L; Orbach D; Pluchart C; Réguerre Y; Rigaud C; Sarnacki S; Sirvent N; Stephan JL; Thebaud E; Gimenez-Roqueplo AP; Brugières L
    J Endocr Soc; 2020 May; 4(5):bvaa039. PubMed ID: 32432211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
    Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.
    Flynn A; Dwight T; Harris J; Benn D; Zhou L; Hogg A; Catchpoole D; James P; Duncan EL; Trainer A; Gill AJ; Clifton-Bligh R; Hicks RJ; Tothill RW
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1034-43. PubMed ID: 26796762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
    Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
    Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma.
    Pipitprapat W; Pattanaprateep O; Iemwimangsa N; Sensorn I; Panthan B; Jiaranai P; Chantratita W; Sorapipatcharoen K; Poomthavorn P; Mahachoklertwattana P; Sura T; Tunteeratum A; Srichan K; Sriphrapradang C
    Ann Med; 2021 Dec; 53(1):1243-1255. PubMed ID: 34309460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
    Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
    J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metastatic risk factors in pheochromocytoma/paraganglioma].
    Rebrova DV; Loginova OI; Vorobyev SL; Vorokhobina NV; Kozorezova ES; Indeykin FA; Savelyeva TV; Sleptsov IV; Chernikov RA; Fedorov EA; Semenov AA; Chinchuk IK; Shikhmagomedov SS; Alekseev MA; Krasnov LM; Rusakov VF
    Probl Endokrinol (Mosk); 2023 Oct; 70(2):37-45. PubMed ID: 38796759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.
    Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.
    Kuo MJM; Nazari MA; Jha A; Pacak K
    Front Endocrinol (Lausanne); 2022; 13():936178. PubMed ID: 35903274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
    Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
    Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of germline mutations in patients with pheochromocytoma and paraganglioma in a tertiary level university hospital: Which patients have been studied and what results have been found?
    Jiménez CM; Quílez RP; Gonzalvo C; Pinés P; Olmos M; Lamas C
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Nov; 65(9):508-514. PubMed ID: 30172768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
    Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
    Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Succinate-Dehydrogenase Deficient Paragangliomas/Pheochromocytomas: Genetics, Clinical Aspects and Mini- Review.
    Rusyn L; Kohn B
    Pediatr Endocrinol Rev; 2017 Mar; 14(3):312-325. PubMed ID: 28508602
    [No Abstract]   [Full Text] [Related]  

  • 37. New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.
    Jhawar S; Arakawa Y; Kumar S; Varghese D; Kim YS; Roper N; Elloumi F; Pommier Y; Pacak K; Del Rivero J
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of germline mutations in Korean patients with pheochromocytoma/paraganglioma.
    Kim JH; Kim MJ; Kong SH; Kim SJ; Kang H; Shin CS; Park SS; Lee KE; Seong MW
    J Med Genet; 2022 Jan; 59(1):56-64. PubMed ID: 33219105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity.
    Vit O; Patel M; Musil Z; Hartmann I; Frysak Z; Miettinen M; Pacak K; Petrak J
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma.
    Hadrava Vanova K; Uher O; Meuter L; Ghosal S; Talvacchio S; Patel M; Neuzil J; Pacak K
    Front Oncol; 2022; 12():1045517. PubMed ID: 36439433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.